KAPA · Kairos Pharma, LTD.
$1.55
-0.10 (-6.06%)
At close · Sep 2
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has experienced recurring losses from operations since inception and incurred a net loss of $3,042 and used cash in operations of $2,048 during the six months ended June 30, 2026. These factors raise substantial doubt about the Company's ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$5.59M
Shares
3.39M
Registered funds — mutual funds, ETFs and closed-end funds — whose latest Form N-PORT portfolio report holds this stock, matched by the stock's CUSIP. Each row is one fund position with its size, value and weight in that fund.
Funds holding KAPA
5 fund positions| Fund | Ticker | Balance | Value | % of Fund | Side | Reported | Open |
|---|---|---|---|---|---|---|---|
| VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND | — | 163,934 | $62,901 | 0.00% | Long | 2026-06-30 | |
| Fidelity Extended Market Index Fund | FSMAX | 81,151 | $41,338 | 0.00% | Long | 2026-05-31 | |
| VANGUARD EXTENDED MARKET INDEX FUND | — | 67,944 | $26,070 | 0.00% | Long | 2026-06-30 | |
| Fidelity Series Total Market Index Fund | FCFMX | 7,599 | $3,871 | 0.00% | Long | 2026-05-31 | |
| Blackstone Alternative Multi-Strategy Fund | — | 35 | $13 | 0.00% | Long | 2026-06-30 |
Showing 1–5 of 5 positions
Key facts
CIK
1962011
CUSIP
48301N104
13F (30d)
14 filings
14 filers
Visit website
Investor relations